IMVT Strangle Strategy
IMVT (Immunovant, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
IMVT (Immunovant, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $8.79B, a beta of 0.81 versus the broader market, a 52-week range of 14.47-42.62, average daily share volume of 1.7M, a public-listing history dating back to 2019, approximately 315 full-time employees. These structural characteristics shape how IMVT stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.81 places IMVT roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on IMVT?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
IMVT snapshot
As of August 14, 2026, spot at $41.52, ATM IV 70.10%, IV rank 25.66%, expected move 20.10%. The strangle on IMVT below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 35-day expiry.
Why this strangle structure on IMVT specifically: IMVT IV at 70.10% is on the cheap side of its 1-year range, which favors premium-buying structures like a IMVT strangle, with a market-implied 1-standard-deviation move of approximately 20.10% (roughly $8.34 on the underlying). The 35-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated IMVT expiries trade a higher absolute premium for lower per-day decay. Position sizing on IMVT should anchor to the underlying notional of $41.52 per share and to the trader's directional view on IMVT stock.
IMVT strangle setup
The IMVT strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With IMVT at $41.52 on that close, the first option leg uses a $44.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed IMVT chain at a 35-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 IMVT shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $44.00 | $2.55 |
| Buy 1 | Put | $39.00 | $2.20 |
IMVT strangle risk and reward
- Net Premium / Debit
- -$475.00
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- -$475.00
- Breakeven(s)
- $34.25, $48.75
- Risk / Reward Ratio
- Unbounded
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
IMVT strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on IMVT. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$3,424.00 |
| $9.19 | -77.9% | +$2,506.08 |
| $18.37 | -55.8% | +$1,588.16 |
| $27.55 | -33.7% | +$670.24 |
| $36.73 | -11.5% | -$247.68 |
| $45.91 | +10.6% | -$284.40 |
| $55.09 | +32.7% | +$633.52 |
| $64.26 | +54.8% | +$1,551.44 |
| $73.44 | +76.9% | +$2,469.36 |
| $82.62 | +99.0% | +$3,387.28 |
When traders use strangle on IMVT
Strangles on IMVT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IMVT chain.
IMVT thesis for this strangle
The market-implied 1-standard-deviation range for IMVT extends from approximately $33.18 on the downside to $49.86 on the upside. A IMVT long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current IMVT IV rank near 25.66% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on IMVT at 70.10%. As a Healthcare name, IMVT options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to IMVT-specific events.
IMVT strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. IMVT positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move IMVT alongside the broader basket even when IMVT-specific fundamentals are unchanged. Always rebuild the position from current IMVT chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on IMVT?
- A strangle on IMVT is the strangle strategy applied to IMVT (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With IMVT stock at $41.52 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed IMVT chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are IMVT strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the IMVT strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 70.10%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$475.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a IMVT strangle?
- The breakeven for the IMVT strangle priced on this page is roughly $34.25 and $48.75 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The IMVT market-implied 1-standard-deviation expected move in the same options snapshot is approximately 20.10%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on IMVT?
- Strangles on IMVT are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the IMVT chain.
- How does current IMVT implied volatility affect this strangle?
- IMVT ATM IV is at 70.10% with IV rank near 25.66%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.